2023
Design, implementation and preliminary results of a type-2 hybrid cluster-randomized trial of integrating screening and treatment for major depressive disorder into specialty clinics providing opioid agonist therapies in Ukraine
Machavariani E, Bromberg D, Dumchev K, Dvoriak S, Zeziulin O, Morozova O, Esserman D, Pykalo I, Saichuk N, Ivasiy R, Haddad M, Altice F. Design, implementation and preliminary results of a type-2 hybrid cluster-randomized trial of integrating screening and treatment for major depressive disorder into specialty clinics providing opioid agonist therapies in Ukraine. Contemporary Clinical Trials 2023, 131: 107248. PMID: 37263492, PMCID: PMC10527419, DOI: 10.1016/j.cct.2023.107248.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidDepressive Disorder, MajorHumansOpioid-Related DisordersSubstance Abuse, IntravenousUkraineConceptsOpioid agonist therapyMajor depressive disorderCo-occurring disordersAgonist therapyDepressive disorderSpecialty clinicPsychiatric disordersPatient-level outcomesPrevalent psychiatric disordersCluster-randomized trialPoor health outcomesProvider-level dataMDD treatmentTreatment algorithmExperimental armHigh prevalenceDelivery outcomesHealth outcomesSerial surveysClinicPatientsProject ECHOSubstance useMonthsDisorders
2022
Contingency management and pre-exposure prophylaxis adherence support services (CoMPASS): A hybrid type 1 effectiveness-implementation study to promote HIV risk reduction among people who inject drugs
Sung M, Viera A, Esserman D, Tong G, Davidson D, Aiudi S, Bailey G, Buchanan A, Buchelli M, Jenkins M, John B, Kolakowski J, Lame A, Murphy S, Porter E, Simone L, Paris M, Rash C, Edelman E. Contingency management and pre-exposure prophylaxis adherence support services (CoMPASS): A hybrid type 1 effectiveness-implementation study to promote HIV risk reduction among people who inject drugs. Contemporary Clinical Trials 2022, 125: 107037. PMID: 36460267, PMCID: PMC9918697, DOI: 10.1016/j.cct.2022.107037.Peer-Reviewed Original ResearchMeSH KeywordsAnti-HIV AgentsDrug UsersHIV InfectionsHumansPre-Exposure ProphylaxisRisk Reduction BehaviorSubstance Abuse, IntravenousConceptsAdherence support servicesHIV risk reductionPrEP adherenceContingency managementHybrid type 1 effectiveness-implementation trialHIV pre-exposure prophylaxisEffectiveness-implementation studyPre-exposure prophylaxisEffectiveness-implementation trialOpioid use disorderStrengths-based case managementRisk reductionSupport servicesCommunity-based programsPrEP initiationPrimary outcomeWeek 12Clinical trialsHIV preventionUse disordersCM sessionsCase managementBlood spotsPWIDStudy design